ACROFAN

Global Lennox-Gastaut Syndrome Treatment Market 2019-2023 - Key Players are Eisai, GlaxoSmithKline, H. Lundbeck, Johnson & Johnson Services, and Super

Published : Monday, April 22, 2019, 2:11 am
ACROFAN=Businesswire | webmaster@businesswire.com | SNS

DUBLIN--(BUSINESS WIRE)--The "Global Lennox-Gastaut Syndrome Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.


The lennox-gastaut syndrome treatment market will register a CAGR of almost 5% by 2023.

The rising population with risk factors for LGS is one of the key factors expected to drive the lennox-gastaut syndrome treatment market growth in the forthcoming years.

The growing prevalence of infectious diseases including encephalitis and meningitis will further increase the risk of the development of LGS. As a result, a rising number of patients with these risk factors will drive the LGS treatment market growth during the forecast period.

Rising population with risk factors for LGS

One of the growth drivers of the global lennox-gastaut syndrome treatment market is the rising population with risk factors for LGS. This will increase the prevalence of LGS which is expected to drive the growth of the lennox-gastaut syndrome treatment market during the forecast period.

Side effects associated with available treatment

One of the challenges in the growth of global lennox-gastaut syndrome treatment market is the side effects associated with available treatment. Several side effects of available treatment are expected to reduce patient adherence to LGS treatments, which will adversely affect the global lennox-gastaut syndrome treatment market during the forecast period.

Competitive Landscape

The market appears to be moderately fragmented with the presence of several market players. Various vendors in the market are forming strategic alliances to improve the research on developing better medications for the treatment of LGS.

This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Key Players

  • Eisai Co. Ltd.
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Johnson & Johnson Services Inc.
  • Supernus Pharmaceuticals Inc.

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY TYPE

  • Comparison by type
  • Non-surgical treatment - Market size and forecast 2018-2023
  • Surgical treatment - Market size and forecast 2018-2023
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • RoW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Eisai Co. Ltd.
  • GlaxoSmithKline PLC
  • H. Lundbeck A/S
  • Johnson & Johnson Services Inc.
  • Supernus Pharmaceuticals Inc.

For more information about this report visit https://www.researchandmarkets.com/r/qb26xx


Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs



Copyright ⓒ Acrofan/Business Wire All Right Reserved


Company Name : ACROFAN
Founded : October 1, 2006
Ownership : Jae-Yong Ryu, Founder.
Headquarters : 1407Ho, Yangpyeongro 12gagil 14, Yeongdeungpo District, Seoul, Republic of Korea(South Korea). Postal Code 07222.
Contact Us : guide@acrofan.com
Contents API : RSS
Copyright(c) ACROFAN All Right Reserved